Search Results

Displaying Results 76-84 of 84 "'KMT'"

Nov 18, 2025, 06:30 ET Kennametal to Attend UBS Global Industrials & Transportation Conference

PITTSBURGH, Nov. 18, 2025 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that they will attend the UBS Global Industrials & Transportation Conference in Manalapan, FL. Details of

More news about: Kennametal Inc.


Nov 13, 2025, 09:00 ET Taiho Oncology Announces 14 Presentations, Including Six Oral Presentations, at the 67th American Society of Hematology Annual Meeting and Exposition

Data from a Phase 2 study evaluating the all-oral combination of ASTX727, venetoclax and revumenib in newly diagnosed AML patients with NPM1m, KMT2Ar or NUP98r AML mutations. Results of a Phase 1/2 clinical trial of the combination of oral decitabine/cedazuridine with

More news about: Taiho Oncology


Nov 05, 2025, 06:30 ET Kennametal Announces Fiscal 2026 First Quarter Results

PITTSBURGH, Nov. 5, 2025 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today reported results for its fiscal 2026 first quarter ended September 30, 2025. "Our first quarter started

More news about: Kennametal Inc.


Nov 03, 2025, 09:00 ET Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting

promising clinical activity across a wide range of potentially therapeutic doses in patients with relapsed or refractory acute leukemia with KMT2A-rearranged (KMT2Ar), NPM1-mutated (NPM1m), and other HOXA9/MEIS1-driven leukemia subtypes. Enzomenib is designed to target the menin and mixed-lineage

More news about: Sumitomo Pharma America


Oct 15, 2025, 06:30 ET Kennametal to Host Earnings Conference Call & Webcast on First Quarter Fiscal 2026 Results

PITTSBURGH, Oct. 15, 2025 /PRNewswire/ -- Kennametal Inc. (NYSE:  KMT) will host its first quarter fiscal year 2026 earnings call on Wednesday, November 5, 2025.  The press release and presentation will be available on

More news about: Kennametal Inc.


Oct 01, 2025, 08:00 ET Kennametal Recognized Among Top of Caterpillar's Indirect Suppliers for Second Consecutive Year

PITTSBURGH, Oct. 1, 2025 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that it has been recognized for a second consecutive year as one of Caterpillar's top indirect suppliers.

More news about: Kennametal Inc.


Sep 24, 2025, 08:13 ET Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

HT-001 MENIN inhibitors are an emerging class of targeted oncology drugs designed to block the interaction between the menin protein and MLL1/KMT2A fusion proteins — genetic drivers implicated in acute leukemias and other cancers. Early clinical data from leading oncology companies have shown that

More news about: Hoth Therapeutics, Inc.


Sep 10, 2025, 11:09 ET Kennametal Named Among World's Best Companies by TIME

PITTSBURGH, Sept. 10, 2025 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) today announced it has been named to TIME's list of

More news about: Kennametal Inc.


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.